What is the price target for TECX stock?
15 analysts have analysed TECX and the average price target is 80.96 USD. This implies a price increase of 143.06% is expected in the next year compared to the current price of 33.31.
NASDAQ:TECX • US8789721086
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for TECTONIC THERAPEUTIC INC (TECX).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-01-08 | Truist Securities | Maintains | Buy -> Buy |
| 2025-09-03 | Oppenheimer | Initiate | Outperform |
| 2025-07-21 | Truist Securities | Initiate | Buy |
| 2025-06-11 | Raymond James | Reiterate | Outperform |
| 2025-06-06 | LifeSci Capital | Initiate | Outperform |
| 2025-05-15 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-04-21 | Mizuho | Initiate | Outperform |
| 2025-03-21 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-01-31 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2024-11-20 | Raymond James | Initiate | Outperform |
| 2024-11-12 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2024-11-11 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2024-08-22 | Wells Fargo | Initiate | Overweight |
| 2024-07-24 | Leerink Partners | Initiate | Outperform |
| 2024-06-26 | Piper Sandler | Initiate | Overweight |
| 2024-06-24 | TD Cowen | Initiate | Buy |
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |||||
| EBITDA YoY % growth | N/A | N/A -70.63% | N/A -79.81% | -15.246M 88.25% | -31.824M -108.74% | -124.09M -289.93% | -56.37M 54.57% | N/A -42.95% | N/A -12.66% | N/A -17.98% | N/A | |
| EBIT YoY % growth | N/A | N/A -69.45% | N/A -74.68% | -15.61M 87.81% | -32.83M -110.31% | -125.568M -282.48% | -58.015M 53.80% | N/A -50.43% | N/A -20.78% | N/A -24.73% | N/A 99.07% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | -32.16 16.63% | -39.72 -23.51% | -33.48 15.71% | -28.92 13.62% | -18.96 34.44% | -8.18 56.86% | -4.05 50.49% | N/A -21.25% | N/A -5.67% | N/A 0.14% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -1.17 -25.58% | -1.22 -13.63% | -1.37 -34.00% | -1.35 -31.38% |
| Revenue Q2Q % growth | ||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -24.041M -31.38% | -26.404M -18.24% | -28.588M -30.60% | -29.358M -20.94% |
All data in USD
15 analysts have analysed TECX and the average price target is 80.96 USD. This implies a price increase of 143.06% is expected in the next year compared to the current price of 33.31.
TECTONIC THERAPEUTIC INC (TECX) will report earnings on 2026-05-06.
The consensus EPS estimate for the next earnings of TECTONIC THERAPEUTIC INC (TECX) is -1.17 USD and the consensus revenue estimate is 0 USD.
The consensus rating for TECTONIC THERAPEUTIC INC (TECX) is 84 / 100 . This indicates that analysts generally have a positive outlook on the stock.